CryoLife seeks partner for FibRX:
This article was originally published in Clinica
Executive Summary
CryoLife is now free to discuss partnerships and license agreements for its fibrin-based bioadhesive, FibRX. In March, Bayer paid CryoLife $250,000 for exclusive rights to negotiate a licence, but no agreement was made (see Clinica No 699, p 13). CryoLife, which is based in Atlanta, Georgia, plans to apply for FDA approval to begin human trials for FibRX in the second quarter of 1997.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.